In ostesarcoma and Ewing sarcoma preclinical models, EphA2-directed chimeric antigen receptor (CAR) T-cell therapy showed potent in vitro and in vivo anti-tumor efficacy [216]. The gene discussed is EPHA2; the disease is neoplasm.